nodes	percent_of_prediction	percent_of_DWPC	metapath
Cevimeline—CYP2D6—Gefitinib—lung cancer	0.0573	0.125	CbGbCtD
Cevimeline—CYP2D6—Vinorelbine—lung cancer	0.0441	0.096	CbGbCtD
Cevimeline—CYP3A4—Topotecan—lung cancer	0.0398	0.0867	CbGbCtD
Cevimeline—CYP3A4—Gefitinib—lung cancer	0.0364	0.0793	CbGbCtD
Cevimeline—CYP3A4—Teniposide—lung cancer	0.0353	0.0769	CbGbCtD
Cevimeline—CYP2D6—Erlotinib—lung cancer	0.0339	0.0737	CbGbCtD
Cevimeline—CYP3A4—Vinorelbine—lung cancer	0.028	0.0611	CbGbCtD
Cevimeline—CYP2D6—Vinblastine—lung cancer	0.0272	0.0592	CbGbCtD
Cevimeline—CYP3A4—Crizotinib—lung cancer	0.0223	0.0486	CbGbCtD
Cevimeline—CYP3A4—Erlotinib—lung cancer	0.0215	0.0469	CbGbCtD
Cevimeline—CYP3A4—Paclitaxel—lung cancer	0.0197	0.0429	CbGbCtD
Cevimeline—CYP3A4—Irinotecan—lung cancer	0.0194	0.0423	CbGbCtD
Cevimeline—CYP3A4—Vinblastine—lung cancer	0.0173	0.0376	CbGbCtD
Cevimeline—CYP2D6—Doxorubicin—lung cancer	0.0167	0.0364	CbGbCtD
Cevimeline—CYP3A4—Etoposide—lung cancer	0.0156	0.0339	CbGbCtD
Cevimeline—CYP3A4—Docetaxel—lung cancer	0.0142	0.031	CbGbCtD
Cevimeline—CYP3A4—Doxorubicin—lung cancer	0.0106	0.0231	CbGbCtD
Cevimeline—Dyspnoea—Paclitaxel—lung cancer	0.000101	0.000243	CcSEcCtD
Cevimeline—Somnolence—Paclitaxel—lung cancer	0.0001	0.000242	CcSEcCtD
Cevimeline—Decreased appetite—Etoposide—lung cancer	0.0001	0.000241	CcSEcCtD
Cevimeline—Myalgia—Docetaxel—lung cancer	9.98e-05	0.000241	CcSEcCtD
Cevimeline—Chest pain—Docetaxel—lung cancer	9.98e-05	0.000241	CcSEcCtD
Cevimeline—Arthralgia—Docetaxel—lung cancer	9.98e-05	0.000241	CcSEcCtD
Cevimeline—Nausea—Vinorelbine—lung cancer	9.97e-05	0.00024	CcSEcCtD
Cevimeline—Dyspepsia—Paclitaxel—lung cancer	9.94e-05	0.000239	CcSEcCtD
Cevimeline—Body temperature increased—Cisplatin—lung cancer	9.93e-05	0.000239	CcSEcCtD
Cevimeline—Asthenia—Irinotecan—lung cancer	9.93e-05	0.000239	CcSEcCtD
Cevimeline—Fatigue—Etoposide—lung cancer	9.93e-05	0.000239	CcSEcCtD
Cevimeline—Constipation—Etoposide—lung cancer	9.84e-05	0.000237	CcSEcCtD
Cevimeline—Pain—Etoposide—lung cancer	9.84e-05	0.000237	CcSEcCtD
Cevimeline—Dysuria—Doxorubicin—lung cancer	9.82e-05	0.000237	CcSEcCtD
Cevimeline—Decreased appetite—Paclitaxel—lung cancer	9.81e-05	0.000236	CcSEcCtD
Cevimeline—Upper respiratory tract infection—Doxorubicin—lung cancer	9.76e-05	0.000235	CcSEcCtD
Cevimeline—Haemoglobin—Methotrexate—lung cancer	9.76e-05	0.000235	CcSEcCtD
Cevimeline—Fatigue—Paclitaxel—lung cancer	9.73e-05	0.000235	CcSEcCtD
Cevimeline—Haemorrhage—Methotrexate—lung cancer	9.71e-05	0.000234	CcSEcCtD
Cevimeline—Pollakiuria—Doxorubicin—lung cancer	9.7e-05	0.000234	CcSEcCtD
Cevimeline—Asthenia—Gemcitabine—lung cancer	9.67e-05	0.000233	CcSEcCtD
Cevimeline—Pain—Paclitaxel—lung cancer	9.65e-05	0.000233	CcSEcCtD
Cevimeline—Constipation—Paclitaxel—lung cancer	9.65e-05	0.000233	CcSEcCtD
Cevimeline—Confusional state—Docetaxel—lung cancer	9.65e-05	0.000233	CcSEcCtD
Cevimeline—Pharyngitis—Methotrexate—lung cancer	9.63e-05	0.000232	CcSEcCtD
Cevimeline—Photosensitivity reaction—Doxorubicin—lung cancer	9.58e-05	0.000231	CcSEcCtD
Cevimeline—Oedema—Docetaxel—lung cancer	9.57e-05	0.000231	CcSEcCtD
Cevimeline—Weight increased—Doxorubicin—lung cancer	9.56e-05	0.00023	CcSEcCtD
Cevimeline—Pruritus—Gemcitabine—lung cancer	9.54e-05	0.00023	CcSEcCtD
Cevimeline—Urethral disorder—Methotrexate—lung cancer	9.51e-05	0.000229	CcSEcCtD
Cevimeline—Infection—Docetaxel—lung cancer	9.5e-05	0.000229	CcSEcCtD
Cevimeline—Weight decreased—Doxorubicin—lung cancer	9.5e-05	0.000229	CcSEcCtD
Cevimeline—Feeling abnormal—Etoposide—lung cancer	9.49e-05	0.000229	CcSEcCtD
Cevimeline—Hyperglycaemia—Doxorubicin—lung cancer	9.47e-05	0.000228	CcSEcCtD
Cevimeline—Diarrhoea—Irinotecan—lung cancer	9.47e-05	0.000228	CcSEcCtD
Cevimeline—Pneumonia—Doxorubicin—lung cancer	9.42e-05	0.000227	CcSEcCtD
Cevimeline—Gastrointestinal pain—Etoposide—lung cancer	9.41e-05	0.000227	CcSEcCtD
Cevimeline—Shock—Docetaxel—lung cancer	9.41e-05	0.000227	CcSEcCtD
Cevimeline—Nervous system disorder—Docetaxel—lung cancer	9.38e-05	0.000226	CcSEcCtD
Cevimeline—Thrombocytopenia—Docetaxel—lung cancer	9.37e-05	0.000226	CcSEcCtD
Cevimeline—Visual impairment—Methotrexate—lung cancer	9.35e-05	0.000225	CcSEcCtD
Cevimeline—Tachycardia—Docetaxel—lung cancer	9.34e-05	0.000225	CcSEcCtD
Cevimeline—Feeling abnormal—Paclitaxel—lung cancer	9.3e-05	0.000224	CcSEcCtD
Cevimeline—Skin disorder—Docetaxel—lung cancer	9.29e-05	0.000224	CcSEcCtD
Cevimeline—Hypersensitivity—Cisplatin—lung cancer	9.26e-05	0.000223	CcSEcCtD
Cevimeline—Gastrointestinal pain—Paclitaxel—lung cancer	9.23e-05	0.000222	CcSEcCtD
Cevimeline—Diarrhoea—Gemcitabine—lung cancer	9.22e-05	0.000222	CcSEcCtD
Cevimeline—Neuropathy peripheral—Doxorubicin—lung cancer	9.18e-05	0.000221	CcSEcCtD
Cevimeline—Dizziness—Irinotecan—lung cancer	9.15e-05	0.000221	CcSEcCtD
Cevimeline—Urticaria—Etoposide—lung cancer	9.15e-05	0.00022	CcSEcCtD
Cevimeline—Stomatitis—Doxorubicin—lung cancer	9.13e-05	0.00022	CcSEcCtD
Cevimeline—Anorexia—Docetaxel—lung cancer	9.12e-05	0.00022	CcSEcCtD
Cevimeline—Abdominal pain—Etoposide—lung cancer	9.1e-05	0.000219	CcSEcCtD
Cevimeline—Body temperature increased—Etoposide—lung cancer	9.1e-05	0.000219	CcSEcCtD
Cevimeline—Conjunctivitis—Doxorubicin—lung cancer	9.1e-05	0.000219	CcSEcCtD
Cevimeline—Urinary tract infection—Doxorubicin—lung cancer	9.1e-05	0.000219	CcSEcCtD
Cevimeline—Eye disorder—Methotrexate—lung cancer	9.07e-05	0.000219	CcSEcCtD
Cevimeline—Tinnitus—Methotrexate—lung cancer	9.05e-05	0.000218	CcSEcCtD
Cevimeline—Asthenia—Cisplatin—lung cancer	9.02e-05	0.000217	CcSEcCtD
Cevimeline—Cardiac disorder—Methotrexate—lung cancer	9.01e-05	0.000217	CcSEcCtD
Cevimeline—Urticaria—Paclitaxel—lung cancer	8.97e-05	0.000216	CcSEcCtD
Cevimeline—Hypotension—Docetaxel—lung cancer	8.94e-05	0.000215	CcSEcCtD
Cevimeline—Haematuria—Doxorubicin—lung cancer	8.93e-05	0.000215	CcSEcCtD
Cevimeline—Abdominal pain—Paclitaxel—lung cancer	8.92e-05	0.000215	CcSEcCtD
Cevimeline—Body temperature increased—Paclitaxel—lung cancer	8.92e-05	0.000215	CcSEcCtD
Cevimeline—Epistaxis—Doxorubicin—lung cancer	8.83e-05	0.000213	CcSEcCtD
Cevimeline—Angiopathy—Methotrexate—lung cancer	8.81e-05	0.000212	CcSEcCtD
Cevimeline—Vomiting—Irinotecan—lung cancer	8.8e-05	0.000212	CcSEcCtD
Cevimeline—Sinusitis—Doxorubicin—lung cancer	8.78e-05	0.000212	CcSEcCtD
Cevimeline—Agranulocytosis—Doxorubicin—lung cancer	8.74e-05	0.000211	CcSEcCtD
Cevimeline—Rash—Irinotecan—lung cancer	8.73e-05	0.00021	CcSEcCtD
Cevimeline—Dermatitis—Irinotecan—lung cancer	8.72e-05	0.00021	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Docetaxel—lung cancer	8.72e-05	0.00021	CcSEcCtD
Cevimeline—Chills—Methotrexate—lung cancer	8.71e-05	0.00021	CcSEcCtD
Cevimeline—Headache—Irinotecan—lung cancer	8.67e-05	0.000209	CcSEcCtD
Cevimeline—Insomnia—Docetaxel—lung cancer	8.65e-05	0.000209	CcSEcCtD
Cevimeline—Diarrhoea—Cisplatin—lung cancer	8.6e-05	0.000207	CcSEcCtD
Cevimeline—Paraesthesia—Docetaxel—lung cancer	8.59e-05	0.000207	CcSEcCtD
Cevimeline—Alopecia—Methotrexate—lung cancer	8.58e-05	0.000207	CcSEcCtD
Cevimeline—Vomiting—Gemcitabine—lung cancer	8.57e-05	0.000207	CcSEcCtD
Cevimeline—Dyspnoea—Docetaxel—lung cancer	8.53e-05	0.000206	CcSEcCtD
Cevimeline—Somnolence—Docetaxel—lung cancer	8.51e-05	0.000205	CcSEcCtD
Cevimeline—Rash—Gemcitabine—lung cancer	8.5e-05	0.000205	CcSEcCtD
Cevimeline—Dermatitis—Gemcitabine—lung cancer	8.49e-05	0.000205	CcSEcCtD
Cevimeline—Hypersensitivity—Etoposide—lung cancer	8.48e-05	0.000204	CcSEcCtD
Cevimeline—Malnutrition—Methotrexate—lung cancer	8.45e-05	0.000204	CcSEcCtD
Cevimeline—Haemoglobin—Doxorubicin—lung cancer	8.45e-05	0.000204	CcSEcCtD
Cevimeline—Headache—Gemcitabine—lung cancer	8.45e-05	0.000204	CcSEcCtD
Cevimeline—Rhinitis—Doxorubicin—lung cancer	8.43e-05	0.000203	CcSEcCtD
Cevimeline—Dyspepsia—Docetaxel—lung cancer	8.42e-05	0.000203	CcSEcCtD
Cevimeline—Haemorrhage—Doxorubicin—lung cancer	8.4e-05	0.000203	CcSEcCtD
Cevimeline—Hypoaesthesia—Doxorubicin—lung cancer	8.36e-05	0.000202	CcSEcCtD
Cevimeline—Pharyngitis—Doxorubicin—lung cancer	8.34e-05	0.000201	CcSEcCtD
Cevimeline—Decreased appetite—Docetaxel—lung cancer	8.32e-05	0.0002	CcSEcCtD
Cevimeline—Hypersensitivity—Paclitaxel—lung cancer	8.32e-05	0.0002	CcSEcCtD
Cevimeline—Oedema peripheral—Doxorubicin—lung cancer	8.28e-05	0.0002	CcSEcCtD
Cevimeline—Dysgeusia—Methotrexate—lung cancer	8.27e-05	0.000199	CcSEcCtD
Cevimeline—Asthenia—Etoposide—lung cancer	8.26e-05	0.000199	CcSEcCtD
Cevimeline—Fatigue—Docetaxel—lung cancer	8.25e-05	0.000199	CcSEcCtD
Cevimeline—Urethral disorder—Doxorubicin—lung cancer	8.24e-05	0.000199	CcSEcCtD
Cevimeline—Nausea—Irinotecan—lung cancer	8.22e-05	0.000198	CcSEcCtD
Cevimeline—Pain—Docetaxel—lung cancer	8.18e-05	0.000197	CcSEcCtD
Cevimeline—Constipation—Docetaxel—lung cancer	8.18e-05	0.000197	CcSEcCtD
Cevimeline—Back pain—Methotrexate—lung cancer	8.17e-05	0.000197	CcSEcCtD
Cevimeline—Pruritus—Etoposide—lung cancer	8.14e-05	0.000196	CcSEcCtD
Cevimeline—Visual impairment—Doxorubicin—lung cancer	8.1e-05	0.000195	CcSEcCtD
Cevimeline—Asthenia—Paclitaxel—lung cancer	8.1e-05	0.000195	CcSEcCtD
Cevimeline—Nausea—Gemcitabine—lung cancer	8.01e-05	0.000193	CcSEcCtD
Cevimeline—Vomiting—Cisplatin—lung cancer	7.99e-05	0.000193	CcSEcCtD
Cevimeline—Pruritus—Paclitaxel—lung cancer	7.99e-05	0.000192	CcSEcCtD
Cevimeline—Rash—Cisplatin—lung cancer	7.92e-05	0.000191	CcSEcCtD
Cevimeline—Dermatitis—Cisplatin—lung cancer	7.92e-05	0.000191	CcSEcCtD
Cevimeline—Feeling abnormal—Docetaxel—lung cancer	7.88e-05	0.00019	CcSEcCtD
Cevimeline—Diarrhoea—Etoposide—lung cancer	7.88e-05	0.00019	CcSEcCtD
Cevimeline—Eye disorder—Doxorubicin—lung cancer	7.85e-05	0.000189	CcSEcCtD
Cevimeline—Ill-defined disorder—Methotrexate—lung cancer	7.84e-05	0.000189	CcSEcCtD
Cevimeline—Tinnitus—Doxorubicin—lung cancer	7.84e-05	0.000189	CcSEcCtD
Cevimeline—Gastrointestinal pain—Docetaxel—lung cancer	7.82e-05	0.000189	CcSEcCtD
Cevimeline—Anaemia—Methotrexate—lung cancer	7.81e-05	0.000188	CcSEcCtD
Cevimeline—Flushing—Doxorubicin—lung cancer	7.8e-05	0.000188	CcSEcCtD
Cevimeline—Cardiac disorder—Doxorubicin—lung cancer	7.8e-05	0.000188	CcSEcCtD
Cevimeline—Diarrhoea—Paclitaxel—lung cancer	7.72e-05	0.000186	CcSEcCtD
Cevimeline—Angiopathy—Doxorubicin—lung cancer	7.63e-05	0.000184	CcSEcCtD
Cevimeline—Malaise—Methotrexate—lung cancer	7.62e-05	0.000184	CcSEcCtD
Cevimeline—Dizziness—Etoposide—lung cancer	7.61e-05	0.000183	CcSEcCtD
Cevimeline—Vertigo—Methotrexate—lung cancer	7.59e-05	0.000183	CcSEcCtD
Cevimeline—Abdominal pain—Docetaxel—lung cancer	7.56e-05	0.000182	CcSEcCtD
Cevimeline—Body temperature increased—Docetaxel—lung cancer	7.56e-05	0.000182	CcSEcCtD
Cevimeline—Leukopenia—Methotrexate—lung cancer	7.56e-05	0.000182	CcSEcCtD
Cevimeline—Chills—Doxorubicin—lung cancer	7.54e-05	0.000182	CcSEcCtD
Cevimeline—Arrhythmia—Doxorubicin—lung cancer	7.51e-05	0.000181	CcSEcCtD
Cevimeline—Dizziness—Paclitaxel—lung cancer	7.46e-05	0.00018	CcSEcCtD
Cevimeline—Nausea—Cisplatin—lung cancer	7.46e-05	0.00018	CcSEcCtD
Cevimeline—Alopecia—Doxorubicin—lung cancer	7.43e-05	0.000179	CcSEcCtD
Cevimeline—Cough—Methotrexate—lung cancer	7.37e-05	0.000178	CcSEcCtD
Cevimeline—Convulsion—Methotrexate—lung cancer	7.32e-05	0.000176	CcSEcCtD
Cevimeline—Vomiting—Etoposide—lung cancer	7.32e-05	0.000176	CcSEcCtD
Cevimeline—Malnutrition—Doxorubicin—lung cancer	7.32e-05	0.000176	CcSEcCtD
Cevimeline—Rash—Etoposide—lung cancer	7.26e-05	0.000175	CcSEcCtD
Cevimeline—Dermatitis—Etoposide—lung cancer	7.25e-05	0.000175	CcSEcCtD
Cevimeline—Headache—Etoposide—lung cancer	7.21e-05	0.000174	CcSEcCtD
Cevimeline—Flatulence—Doxorubicin—lung cancer	7.21e-05	0.000174	CcSEcCtD
Cevimeline—Myalgia—Methotrexate—lung cancer	7.19e-05	0.000173	CcSEcCtD
Cevimeline—Chest pain—Methotrexate—lung cancer	7.19e-05	0.000173	CcSEcCtD
Cevimeline—Arthralgia—Methotrexate—lung cancer	7.19e-05	0.000173	CcSEcCtD
Cevimeline—Vomiting—Paclitaxel—lung cancer	7.18e-05	0.000173	CcSEcCtD
Cevimeline—Dysgeusia—Doxorubicin—lung cancer	7.16e-05	0.000173	CcSEcCtD
Cevimeline—Rash—Paclitaxel—lung cancer	7.12e-05	0.000172	CcSEcCtD
Cevimeline—Dermatitis—Paclitaxel—lung cancer	7.11e-05	0.000171	CcSEcCtD
Cevimeline—Discomfort—Methotrexate—lung cancer	7.11e-05	0.000171	CcSEcCtD
Cevimeline—Back pain—Doxorubicin—lung cancer	7.08e-05	0.000171	CcSEcCtD
Cevimeline—Headache—Paclitaxel—lung cancer	7.07e-05	0.00017	CcSEcCtD
Cevimeline—Hypersensitivity—Docetaxel—lung cancer	7.05e-05	0.00017	CcSEcCtD
Cevimeline—Muscle spasms—Doxorubicin—lung cancer	7.03e-05	0.00017	CcSEcCtD
Cevimeline—Confusional state—Methotrexate—lung cancer	6.95e-05	0.000168	CcSEcCtD
Cevimeline—Asthenia—Docetaxel—lung cancer	6.86e-05	0.000165	CcSEcCtD
Cevimeline—Infection—Methotrexate—lung cancer	6.85e-05	0.000165	CcSEcCtD
Cevimeline—Nausea—Etoposide—lung cancer	6.84e-05	0.000165	CcSEcCtD
Cevimeline—Ill-defined disorder—Doxorubicin—lung cancer	6.79e-05	0.000164	CcSEcCtD
Cevimeline—Pruritus—Docetaxel—lung cancer	6.77e-05	0.000163	CcSEcCtD
Cevimeline—Nervous system disorder—Methotrexate—lung cancer	6.76e-05	0.000163	CcSEcCtD
Cevimeline—Anaemia—Doxorubicin—lung cancer	6.76e-05	0.000163	CcSEcCtD
Cevimeline—Thrombocytopenia—Methotrexate—lung cancer	6.75e-05	0.000163	CcSEcCtD
Cevimeline—Agitation—Doxorubicin—lung cancer	6.72e-05	0.000162	CcSEcCtD
Cevimeline—Nausea—Paclitaxel—lung cancer	6.7e-05	0.000162	CcSEcCtD
Cevimeline—Skin disorder—Methotrexate—lung cancer	6.7e-05	0.000161	CcSEcCtD
Cevimeline—Hyperhidrosis—Methotrexate—lung cancer	6.67e-05	0.000161	CcSEcCtD
Cevimeline—Malaise—Doxorubicin—lung cancer	6.6e-05	0.000159	CcSEcCtD
Cevimeline—Vertigo—Doxorubicin—lung cancer	6.57e-05	0.000158	CcSEcCtD
Cevimeline—Anorexia—Methotrexate—lung cancer	6.57e-05	0.000158	CcSEcCtD
Cevimeline—Syncope—Doxorubicin—lung cancer	6.56e-05	0.000158	CcSEcCtD
Cevimeline—Leukopenia—Doxorubicin—lung cancer	6.55e-05	0.000158	CcSEcCtD
Cevimeline—Diarrhoea—Docetaxel—lung cancer	6.55e-05	0.000158	CcSEcCtD
Cevimeline—Palpitations—Doxorubicin—lung cancer	6.47e-05	0.000156	CcSEcCtD
Cevimeline—Hypotension—Methotrexate—lung cancer	6.44e-05	0.000155	CcSEcCtD
Cevimeline—Loss of consciousness—Doxorubicin—lung cancer	6.43e-05	0.000155	CcSEcCtD
Cevimeline—Cough—Doxorubicin—lung cancer	6.38e-05	0.000154	CcSEcCtD
Cevimeline—Convulsion—Doxorubicin—lung cancer	6.34e-05	0.000153	CcSEcCtD
Cevimeline—Dizziness—Docetaxel—lung cancer	6.33e-05	0.000152	CcSEcCtD
Cevimeline—Hypertension—Doxorubicin—lung cancer	6.32e-05	0.000152	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Methotrexate—lung cancer	6.28e-05	0.000151	CcSEcCtD
Cevimeline—Insomnia—Methotrexate—lung cancer	6.24e-05	0.00015	CcSEcCtD
Cevimeline—Myalgia—Doxorubicin—lung cancer	6.23e-05	0.00015	CcSEcCtD
Cevimeline—Chest pain—Doxorubicin—lung cancer	6.23e-05	0.00015	CcSEcCtD
Cevimeline—Arthralgia—Doxorubicin—lung cancer	6.23e-05	0.00015	CcSEcCtD
Cevimeline—Anxiety—Doxorubicin—lung cancer	6.21e-05	0.00015	CcSEcCtD
Cevimeline—Paraesthesia—Methotrexate—lung cancer	6.19e-05	0.000149	CcSEcCtD
Cevimeline—Discomfort—Doxorubicin—lung cancer	6.15e-05	0.000148	CcSEcCtD
Cevimeline—Dyspnoea—Methotrexate—lung cancer	6.15e-05	0.000148	CcSEcCtD
Cevimeline—Somnolence—Methotrexate—lung cancer	6.13e-05	0.000148	CcSEcCtD
Cevimeline—Vomiting—Docetaxel—lung cancer	6.08e-05	0.000147	CcSEcCtD
Cevimeline—Dyspepsia—Methotrexate—lung cancer	6.07e-05	0.000146	CcSEcCtD
Cevimeline—Rash—Docetaxel—lung cancer	6.03e-05	0.000145	CcSEcCtD
Cevimeline—Dermatitis—Docetaxel—lung cancer	6.03e-05	0.000145	CcSEcCtD
Cevimeline—Confusional state—Doxorubicin—lung cancer	6.02e-05	0.000145	CcSEcCtD
Cevimeline—Decreased appetite—Methotrexate—lung cancer	5.99e-05	0.000144	CcSEcCtD
Cevimeline—Headache—Docetaxel—lung cancer	5.99e-05	0.000144	CcSEcCtD
Cevimeline—Oedema—Doxorubicin—lung cancer	5.97e-05	0.000144	CcSEcCtD
Cevimeline—Fatigue—Methotrexate—lung cancer	5.95e-05	0.000143	CcSEcCtD
Cevimeline—Infection—Doxorubicin—lung cancer	5.93e-05	0.000143	CcSEcCtD
Cevimeline—Pain—Methotrexate—lung cancer	5.9e-05	0.000142	CcSEcCtD
Cevimeline—Shock—Doxorubicin—lung cancer	5.87e-05	0.000142	CcSEcCtD
Cevimeline—Nervous system disorder—Doxorubicin—lung cancer	5.86e-05	0.000141	CcSEcCtD
Cevimeline—Thrombocytopenia—Doxorubicin—lung cancer	5.85e-05	0.000141	CcSEcCtD
Cevimeline—Tachycardia—Doxorubicin—lung cancer	5.83e-05	0.00014	CcSEcCtD
Cevimeline—Skin disorder—Doxorubicin—lung cancer	5.8e-05	0.00014	CcSEcCtD
Cevimeline—Hyperhidrosis—Doxorubicin—lung cancer	5.77e-05	0.000139	CcSEcCtD
Cevimeline—Anorexia—Doxorubicin—lung cancer	5.69e-05	0.000137	CcSEcCtD
Cevimeline—Nausea—Docetaxel—lung cancer	5.68e-05	0.000137	CcSEcCtD
Cevimeline—Feeling abnormal—Methotrexate—lung cancer	5.68e-05	0.000137	CcSEcCtD
Cevimeline—Gastrointestinal pain—Methotrexate—lung cancer	5.64e-05	0.000136	CcSEcCtD
Cevimeline—Hypotension—Doxorubicin—lung cancer	5.58e-05	0.000134	CcSEcCtD
Cevimeline—Urticaria—Methotrexate—lung cancer	5.48e-05	0.000132	CcSEcCtD
Cevimeline—Abdominal pain—Methotrexate—lung cancer	5.45e-05	0.000131	CcSEcCtD
Cevimeline—Body temperature increased—Methotrexate—lung cancer	5.45e-05	0.000131	CcSEcCtD
Cevimeline—Musculoskeletal discomfort—Doxorubicin—lung cancer	5.44e-05	0.000131	CcSEcCtD
Cevimeline—Insomnia—Doxorubicin—lung cancer	5.4e-05	0.00013	CcSEcCtD
Cevimeline—Paraesthesia—Doxorubicin—lung cancer	5.36e-05	0.000129	CcSEcCtD
Cevimeline—Dyspnoea—Doxorubicin—lung cancer	5.32e-05	0.000128	CcSEcCtD
Cevimeline—Somnolence—Doxorubicin—lung cancer	5.31e-05	0.000128	CcSEcCtD
Cevimeline—Dyspepsia—Doxorubicin—lung cancer	5.26e-05	0.000127	CcSEcCtD
Cevimeline—Decreased appetite—Doxorubicin—lung cancer	5.19e-05	0.000125	CcSEcCtD
Cevimeline—Fatigue—Doxorubicin—lung cancer	5.15e-05	0.000124	CcSEcCtD
Cevimeline—Pain—Doxorubicin—lung cancer	5.11e-05	0.000123	CcSEcCtD
Cevimeline—Constipation—Doxorubicin—lung cancer	5.11e-05	0.000123	CcSEcCtD
Cevimeline—Hypersensitivity—Methotrexate—lung cancer	5.08e-05	0.000122	CcSEcCtD
Cevimeline—Asthenia—Methotrexate—lung cancer	4.95e-05	0.000119	CcSEcCtD
Cevimeline—Feeling abnormal—Doxorubicin—lung cancer	4.92e-05	0.000119	CcSEcCtD
Cevimeline—Gastrointestinal pain—Doxorubicin—lung cancer	4.88e-05	0.000118	CcSEcCtD
Cevimeline—Pruritus—Methotrexate—lung cancer	4.88e-05	0.000118	CcSEcCtD
Cevimeline—Urticaria—Doxorubicin—lung cancer	4.74e-05	0.000114	CcSEcCtD
Cevimeline—Abdominal pain—Doxorubicin—lung cancer	4.72e-05	0.000114	CcSEcCtD
Cevimeline—Body temperature increased—Doxorubicin—lung cancer	4.72e-05	0.000114	CcSEcCtD
Cevimeline—Diarrhoea—Methotrexate—lung cancer	4.72e-05	0.000114	CcSEcCtD
Cevimeline—Dizziness—Methotrexate—lung cancer	4.56e-05	0.00011	CcSEcCtD
Cevimeline—Hypersensitivity—Doxorubicin—lung cancer	4.4e-05	0.000106	CcSEcCtD
Cevimeline—Vomiting—Methotrexate—lung cancer	4.38e-05	0.000106	CcSEcCtD
Cevimeline—Rash—Methotrexate—lung cancer	4.35e-05	0.000105	CcSEcCtD
Cevimeline—Dermatitis—Methotrexate—lung cancer	4.34e-05	0.000105	CcSEcCtD
Cevimeline—Headache—Methotrexate—lung cancer	4.32e-05	0.000104	CcSEcCtD
Cevimeline—Asthenia—Doxorubicin—lung cancer	4.28e-05	0.000103	CcSEcCtD
Cevimeline—Pruritus—Doxorubicin—lung cancer	4.22e-05	0.000102	CcSEcCtD
Cevimeline—Nausea—Methotrexate—lung cancer	4.1e-05	9.87e-05	CcSEcCtD
Cevimeline—Diarrhoea—Doxorubicin—lung cancer	4.09e-05	9.85e-05	CcSEcCtD
Cevimeline—Dizziness—Doxorubicin—lung cancer	3.95e-05	9.52e-05	CcSEcCtD
Cevimeline—Vomiting—Doxorubicin—lung cancer	3.8e-05	9.15e-05	CcSEcCtD
Cevimeline—Rash—Doxorubicin—lung cancer	3.76e-05	9.07e-05	CcSEcCtD
Cevimeline—Dermatitis—Doxorubicin—lung cancer	3.76e-05	9.07e-05	CcSEcCtD
Cevimeline—Headache—Doxorubicin—lung cancer	3.74e-05	9.02e-05	CcSEcCtD
Cevimeline—Nausea—Doxorubicin—lung cancer	3.55e-05	8.55e-05	CcSEcCtD
Cevimeline—FMO1—Metabolism—AKT1—lung cancer	2.45e-05	0.000195	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—UGT1A1—lung cancer	2.44e-05	0.000194	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—FGF9—lung cancer	2.44e-05	0.000194	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—FGF9—lung cancer	2.43e-05	0.000194	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—MTMR3—lung cancer	2.41e-05	0.000192	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—POMC—lung cancer	2.37e-05	0.000189	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—POMC—lung cancer	2.37e-05	0.000188	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GNG11—lung cancer	2.36e-05	0.000187	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PGAM1—lung cancer	2.35e-05	0.000187	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—GSTP1—lung cancer	2.34e-05	0.000186	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—JUNB—lung cancer	2.33e-05	0.000186	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—JUNB—lung cancer	2.32e-05	0.000185	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—CAT—lung cancer	2.27e-05	0.000181	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—PIK3CG—lung cancer	2.26e-05	0.00018	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—PIK3CG—lung cancer	2.26e-05	0.000179	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ALDOA—lung cancer	2.24e-05	0.000178	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CYP2A7—lung cancer	2.24e-05	0.000178	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—ABCB1—lung cancer	2.21e-05	0.000176	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—SDC4—lung cancer	2.19e-05	0.000175	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—PIK3CD—lung cancer	2.19e-05	0.000174	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—PIK3CD—lung cancer	2.18e-05	0.000174	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—NCOA3—lung cancer	2.18e-05	0.000173	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—TYMS—lung cancer	2.17e-05	0.000173	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—POMC—lung cancer	2.15e-05	0.000171	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—POMC—lung cancer	2.15e-05	0.000171	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—GSTM1—lung cancer	2.15e-05	0.000171	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ADCY1—lung cancer	2.12e-05	0.000169	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ABCG2—lung cancer	2.12e-05	0.000169	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—STK11—lung cancer	2.12e-05	0.000168	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—STK11—lung cancer	2.11e-05	0.000168	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—IL6R—lung cancer	2.1e-05	0.000167	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—IL6R—lung cancer	2.1e-05	0.000167	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ENO2—lung cancer	2.08e-05	0.000165	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—HPGDS—lung cancer	2.08e-05	0.000165	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PPP2R1B—lung cancer	2.06e-05	0.000164	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—FOXO3—lung cancer	2.04e-05	0.000163	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—FOXO3—lung cancer	2.04e-05	0.000162	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—CYP1A1—lung cancer	2.04e-05	0.000162	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—ERCC2—lung cancer	2.02e-05	0.000161	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GSTT1—lung cancer	2.02e-05	0.00016	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—MAP2K1—lung cancer	2e-05	0.000159	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—RRM1—lung cancer	2e-05	0.000159	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GSTA3—lung cancer	2e-05	0.000159	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—MAP2K1—lung cancer	2e-05	0.000159	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GCLC—lung cancer	1.99e-05	0.000158	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CYP2A6—lung cancer	1.99e-05	0.000158	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—PIK3CD—lung cancer	1.99e-05	0.000158	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—PIK3CD—lung cancer	1.98e-05	0.000158	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—AVP—lung cancer	1.92e-05	0.000152	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—PIK3CB—lung cancer	1.91e-05	0.000152	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—AVP—lung cancer	1.91e-05	0.000152	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—PIK3CB—lung cancer	1.9e-05	0.000151	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ENO1—lung cancer	1.89e-05	0.00015	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—B4GALT5—lung cancer	1.88e-05	0.000149	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—IGF1R—lung cancer	1.84e-05	0.000147	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—IGF1R—lung cancer	1.84e-05	0.000146	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—CXCL8—lung cancer	1.84e-05	0.000146	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—CXCL8—lung cancer	1.83e-05	0.000146	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GSTA4—lung cancer	1.83e-05	0.000145	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—HES1—lung cancer	1.81e-05	0.000144	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—HES1—lung cancer	1.81e-05	0.000144	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GSTA2—lung cancer	1.78e-05	0.000142	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—RAF1—lung cancer	1.78e-05	0.000141	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—RAF1—lung cancer	1.77e-05	0.000141	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—IL2—lung cancer	1.75e-05	0.00014	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—IL2—lung cancer	1.75e-05	0.000139	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—APOA1—lung cancer	1.75e-05	0.000139	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—PIK3CB—lung cancer	1.73e-05	0.000138	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—PIK3CB—lung cancer	1.73e-05	0.000138	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GSTA1—lung cancer	1.72e-05	0.000137	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ABCC3—lung cancer	1.7e-05	0.000135	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CYP2E1—lung cancer	1.69e-05	0.000135	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—NQO1—lung cancer	1.67e-05	0.000133	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—CXCL8—lung cancer	1.67e-05	0.000133	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—CXCL8—lung cancer	1.66e-05	0.000132	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—ERBB3—lung cancer	1.66e-05	0.000132	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—ERBB3—lung cancer	1.65e-05	0.000131	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—AKR1C1—lung cancer	1.65e-05	0.000131	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—UGT1A1—lung cancer	1.6e-05	0.000127	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PIK3CG—lung cancer	1.59e-05	0.000127	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—IL2—lung cancer	1.59e-05	0.000127	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—IL2—lung cancer	1.59e-05	0.000126	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—TERT—lung cancer	1.59e-05	0.000126	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—TERT—lung cancer	1.58e-05	0.000126	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—FGFR1—lung cancer	1.54e-05	0.000123	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GNG11—lung cancer	1.54e-05	0.000123	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—FGFR1—lung cancer	1.54e-05	0.000122	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—HIF1A—lung cancer	1.52e-05	0.000121	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—POMC—lung cancer	1.52e-05	0.000121	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—HIF1A—lung cancer	1.51e-05	0.00012	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—STK11—lung cancer	1.51e-05	0.00012	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—CREBBP—lung cancer	1.48e-05	0.000118	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ALDOA—lung cancer	1.47e-05	0.000117	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—APOA1—lung cancer	1.46e-05	0.000117	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—APOA1—lung cancer	1.46e-05	0.000116	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—KDR—lung cancer	1.45e-05	0.000115	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—KDR—lung cancer	1.45e-05	0.000115	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—NCOA3—lung cancer	1.42e-05	0.000113	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PIK3CD—lung cancer	1.4e-05	0.000111	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GSTP1—lung cancer	1.4e-05	0.000111	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ADCY1—lung cancer	1.39e-05	0.00011	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ABCG2—lung cancer	1.39e-05	0.00011	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—ALB—lung cancer	1.38e-05	0.00011	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CAT—lung cancer	1.36e-05	0.000108	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—HPGDS—lung cancer	1.36e-05	0.000108	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ENO2—lung cancer	1.36e-05	0.000108	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PPP2R1B—lung cancer	1.35e-05	0.000107	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PIK3CG—lung cancer	1.34e-05	0.000106	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—KIT—lung cancer	1.34e-05	0.000106	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—APC—lung cancer	1.34e-05	0.000106	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—NRAS—lung cancer	1.34e-05	0.000106	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—APC—lung cancer	1.33e-05	0.000106	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—KIT—lung cancer	1.33e-05	0.000106	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PIK3CG—lung cancer	1.33e-05	0.000106	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—NRAS—lung cancer	1.33e-05	0.000106	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ABCB1—lung cancer	1.32e-05	0.000105	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—EGF—lung cancer	1.32e-05	0.000105	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GSTT1—lung cancer	1.32e-05	0.000105	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—EGF—lung cancer	1.32e-05	0.000105	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GCLC—lung cancer	1.3e-05	0.000104	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CYP2A6—lung cancer	1.3e-05	0.000104	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—TYMS—lung cancer	1.3e-05	0.000103	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—GSTM1—lung cancer	1.28e-05	0.000102	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—MAPK3—lung cancer	1.28e-05	0.000102	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—MAPK3—lung cancer	1.28e-05	0.000102	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—POMC—lung cancer	1.27e-05	0.000101	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—POMC—lung cancer	1.27e-05	0.000101	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—BRAF—lung cancer	1.26e-05	0.0001	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—BRAF—lung cancer	1.25e-05	9.97e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—IL6R—lung cancer	1.24e-05	9.88e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CREBBP—lung cancer	1.24e-05	9.86e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—IL6R—lung cancer	1.24e-05	9.85e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CREBBP—lung cancer	1.24e-05	9.83e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ENO1—lung cancer	1.23e-05	9.82e-05	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PIK3CB—lung cancer	1.22e-05	9.72e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—EGFR—lung cancer	1.22e-05	9.69e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CYP1A1—lung cancer	1.22e-05	9.68e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—EGFR—lung cancer	1.21e-05	9.66e-05	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PTGS2—lung cancer	1.21e-05	9.63e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ERCC2—lung cancer	1.21e-05	9.6e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MAP2K1—lung cancer	1.18e-05	9.41e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MAP2K1—lung cancer	1.18e-05	9.38e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PIK3CD—lung cancer	1.18e-05	9.35e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PIK3CD—lung cancer	1.17e-05	9.32e-05	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—PIK3CA—lung cancer	1.16e-05	9.26e-05	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—PIK3CA—lung cancer	1.16e-05	9.23e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—KRAS—lung cancer	1.15e-05	9.15e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—KRAS—lung cancer	1.15e-05	9.13e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CYP2E1—lung cancer	1.11e-05	8.81e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—NQO1—lung cancer	1.09e-05	8.71e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—PIK3CA—lung cancer	1.06e-05	8.41e-05	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PTEN—lung cancer	1.06e-05	8.4e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—PIK3CA—lung cancer	1.05e-05	8.38e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MDM2—lung cancer	1.05e-05	8.38e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MDM2—lung cancer	1.05e-05	8.35e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—RAF1—lung cancer	1.05e-05	8.35e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—RAF1—lung cancer	1.05e-05	8.32e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—APOA1—lung cancer	1.04e-05	8.3e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—ERBB2—lung cancer	1.04e-05	8.26e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—ERBB2—lung cancer	1.03e-05	8.23e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MTOR—lung cancer	1.02e-05	8.15e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PIK3CB—lung cancer	1.02e-05	8.15e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MTOR—lung cancer	1.02e-05	8.12e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PIK3CB—lung cancer	1.02e-05	8.12e-05	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—EP300—lung cancer	1.01e-05	8.01e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—STK11—lung cancer	9.87e-06	7.85e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CXCL8—lung cancer	9.85e-06	7.83e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CXCL8—lung cancer	9.81e-06	7.81e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—HRAS—lung cancer	9.78e-06	7.78e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—HRAS—lung cancer	9.75e-06	7.76e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PIK3CG—lung cancer	9.53e-06	7.58e-05	CbGpPWpGaD
Cevimeline—CHRM1—GPCR downstream signaling—AKT1—lung cancer	9.51e-06	7.57e-05	CbGpPWpGaD
Cevimeline—CHRM3—GPCR downstream signaling—AKT1—lung cancer	9.48e-06	7.54e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CASP3—lung cancer	9.42e-06	7.5e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—IL2—lung cancer	9.41e-06	7.49e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CASP3—lung cancer	9.39e-06	7.47e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—IL2—lung cancer	9.38e-06	7.46e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—IL6—lung cancer	9.36e-06	7.45e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—IL6—lung cancer	9.33e-06	7.42e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CCND1—lung cancer	9.17e-06	7.3e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—JUN—lung cancer	9.15e-06	7.28e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CCND1—lung cancer	9.14e-06	7.27e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GSTP1—lung cancer	9.13e-06	7.26e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—JUN—lung cancer	9.12e-06	7.26e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—POMC—lung cancer	9.07e-06	7.22e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MMP9—lung cancer	8.91e-06	7.08e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CAT—lung cancer	8.89e-06	7.07e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MMP9—lung cancer	8.88e-06	7.06e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—CDKN1A—lung cancer	8.87e-06	7.06e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PTEN—lung cancer	8.85e-06	7.04e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—CDKN1A—lung cancer	8.85e-06	7.04e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—CREBBP—lung cancer	8.84e-06	7.03e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PTEN—lung cancer	8.83e-06	7.02e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ABCB1—lung cancer	8.64e-06	6.88e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling by GPCR—AKT1—lung cancer	8.64e-06	6.87e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling by GPCR—AKT1—lung cancer	8.61e-06	6.85e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—TYMS—lung cancer	8.49e-06	6.75e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—EP300—lung cancer	8.44e-06	6.72e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—EP300—lung cancer	8.42e-06	6.7e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—GSTM1—lung cancer	8.39e-06	6.68e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PIK3CD—lung cancer	8.38e-06	6.67e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—ALB—lung cancer	8.27e-06	6.58e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—SRC—lung cancer	8.21e-06	6.53e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—SRC—lung cancer	8.18e-06	6.51e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—VEGFA—lung cancer	8e-06	6.36e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—VEGFA—lung cancer	7.97e-06	6.34e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CYP1A1—lung cancer	7.96e-06	6.33e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—STAT3—lung cancer	7.92e-06	6.3e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—NRAS—lung cancer	7.9e-06	6.28e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—STAT3—lung cancer	7.89e-06	6.28e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ERCC2—lung cancer	7.89e-06	6.28e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—NRAS—lung cancer	7.87e-06	6.26e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MAPK3—lung cancer	7.56e-06	6.02e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MAPK3—lung cancer	7.54e-06	6e-05	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—PIK3CA—lung cancer	7.45e-06	5.92e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—MYC—lung cancer	7.36e-06	5.85e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—MYC—lung cancer	7.33e-06	5.83e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PIK3CB—lung cancer	7.3e-06	5.81e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PTGS2—lung cancer	7.24e-06	5.76e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—EGFR—lung cancer	7.2e-06	5.72e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—EGFR—lung cancer	7.17e-06	5.71e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—APOA1—lung cancer	6.83e-06	5.43e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—KRAS—lung cancer	6.8e-06	5.41e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—KRAS—lung cancer	6.78e-06	5.39e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PTEN—lung cancer	6.31e-06	5.02e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—PIK3CA—lung cancer	6.25e-06	4.97e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PIK3CG—lung cancer	6.23e-06	4.96e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—PIK3CA—lung cancer	6.23e-06	4.95e-05	CbGpPWpGaD
Cevimeline—CHRM3—Metabolism—AKT1—lung cancer	6.08e-06	4.84e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—TP53—lung cancer	6.04e-06	4.81e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—TP53—lung cancer	6.02e-06	4.79e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—EP300—lung cancer	6.02e-06	4.79e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—POMC—lung cancer	5.93e-06	4.72e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—HRAS—lung cancer	5.78e-06	4.6e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—CREBBP—lung cancer	5.78e-06	4.6e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—HRAS—lung cancer	5.76e-06	4.58e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—IL6—lung cancer	5.53e-06	4.4e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—IL6—lung cancer	5.51e-06	4.39e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PIK3CD—lung cancer	5.48e-06	4.36e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—ALB—lung cancer	5.41e-06	4.3e-05	CbGpPWpGaD
Cevimeline—CHRM1—Signaling Pathways—AKT1—lung cancer	5.1e-06	4.06e-05	CbGpPWpGaD
Cevimeline—CHRM3—Signaling Pathways—AKT1—lung cancer	5.09e-06	4.05e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PIK3CB—lung cancer	4.77e-06	3.8e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PTGS2—lung cancer	4.73e-06	3.76e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—PIK3CA—lung cancer	4.45e-06	3.54e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PTEN—lung cancer	4.13e-06	3.28e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—EP300—lung cancer	3.93e-06	3.13e-05	CbGpPWpGaD
Cevimeline—CYP2D6—Metabolism—AKT1—lung cancer	3.64e-06	2.89e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—PIK3CA—lung cancer	2.91e-06	2.32e-05	CbGpPWpGaD
Cevimeline—CYP3A4—Metabolism—AKT1—lung cancer	2.38e-06	1.89e-05	CbGpPWpGaD
